Type 2 diabetes mellitus: A potentially modifiable risk factor for neurochemical brain changes in bipolar disorders

Biological Psychiatry

Volumn 77, Issue 3, 2015, Pages 295-303

  Hajek, Tomas ^a,b   Calkin, Cynthia ^a   Blagdon, Ryan ^a   Slaney, Claire ^a   Alda, Martin ^a,b  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Bipolar disorder; Global assessment of functioning; N acetylaspartate; Prefrontal cortex; Total creatine; Type 2 diabetes mellitus

Indexed keywords

CREATINE; CREATINE PHOSPHATE; GLUCOSE; INSULIN; N ACETYLASPARTIC ACID; ASPARTIC ACID; N-ACETYLASPARTATE;

ADULT; ARTICLE; BIPOLAR DISORDER; BRAIN DAMAGE; BRAIN LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENERGY METABOLISM; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MALE; MIDDLE AGED; NERVE CELL; NEUROIMAGING; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; PATIENT RISK; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SOCIAL PSYCHOLOGY; ANALOGS AND DERIVATIVES; BRAIN; COMPLICATION; CROSS-SECTIONAL STUDY; METABOLISM; PSYCHOLOGICAL RATING SCALE;

ADULT; ASPARTIC ACID; BIPOLAR DISORDER; BRAIN; CREATINE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS;

EID: 84924667663     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2013.11.007     Document Type: Article

References (81)

1. Kempton MJ, Geddes JR, Ettinger U, Williams SC, Grasby PM (2008): Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Arch Gen Psychiatry 65:1017-1032.
2. Hajek T, Kopecek M, Kozeny J, Gunde E, Alda M, Hoschl C (2009): Amygdala volumes in mood disorders-meta-analysis of magnetic resonance volumetry studies. J Affect Disord 115:395-410.
3. Hajek T, Kozeny J, Kopecek M, Alda M, Hoschl C (2008): Reduced subgenual cingulate volumes in mood disorders: A meta-analysis. J Psychiatry Neurosci 33:91-99.
4. Yildiz-Yesiloglu A, Ankerst DP (2006): Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: A systematic review of the in vivo proton magnetic resonance spectroscopy findings. Prog Neuropsychopharmacol Biol Psychiatry 30:969-995.
5. Hajek T, Kopecek M, Alda M, Uher R, Hoschl C (2013): Why negative meta-analyses may be false? Eur Neuropsychopharmacol 23:1307-1309.
6. Lilliker SL (1980): Prevalence of diabetes in a manic-depressive population. Compr Psychiatry 21:270-275.
7. Cassidy F, Ahearn E, Carrol BJ (1999): Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 156:1417-1420.
8. McIntyre RS, Danilewitz M, Liauw SS, Kemp DE, Nguyen HT, Kahn LS, et al. (2010): Bipolar disorder and metabolic syndrome: An international perspective. J Affect Disord 126:366-387.
9. Crump C, Sundquist K, Winkleby MA, Sundquist J (2013): Comorbidities and mortality in bipolar disorder: A Swedish National Cohort Study. JAMA Psychiatry 70:931-939.
10. McIntyre RS, Konarski JZ, Misener VL, Kennedy SH (2005): Bipolar disorder and diabetes mellitus: Epidemiology, etiology, and treatment implications. Ann Clin Psychiatry 17:83-93.
11. Hajek T, Slaney C, Garnham J, Ruzickova M, Passmore M, Alda M (2005): Clinical correlates of current level of functioning in primary care-treated bipolar patients. Bipolar Disord 7:286-291.
12. Hajek T, Hahn M, Slaney C, Garnham J, Green J, Ruzickova M, et al. (2008): Rapid cycling bipolar disorders in primary and tertiary care treated patients. Bipolar Disord 10:495-502.
13. Ruzickova M, Slaney C, Garnham J, Alda M (2003): Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Can J Psychiatry 48:458-461.
14. Calkin C, van de Velde C, Ruzickova M, Slaney C, Garnham J, Hajek T, et al. (2009): Can body mass index help predict outcome in patients with bipolar disorder? Bipolar Disord 11:650-656.
15. Laursen TM, Munk-Olsen T, Agerbo E, Gasse C, Mortensen PB (2009): Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry 66:713-720.
16. Goldberg RW, Kreyenbuhl JA, Medoff DR, Dickerson FB, Wohlheiter K, Fang LJ, et al. (2007): Quality of diabetes care among adults with serious mental illness. Psychiatr Serv 58:536-543.
17. Dixon LB, Kreyenbuhl JA, Dickerson FB, Donner TW, Brown CH, Wohlheiter K, et al. (2004): A comparison of type 2 diabetes outcomes among persons with and without severe mental illnesses. Psychiatr Serv 55:892-900.
18. Kreyenbuhl J, Dickerson FB, Medoff DR, Brown CH, Goldberg RW, Fang L, et al. (2006): Extent and management of cardiovascular risk factors in patients with type 2 diabetes and serious mental illness. J Nerv Ment Dis 194:404-410.
19. Frayne SM, Halanych JH, Miller DR, Wang F, Lin H, Pogach L, et al. (2005): Disparities in diabetes care: Impact of mental illness. Arch Intern Med 165:2631-2638.
20. de la Monte SM (2009): Insulin resistance and Alzheimer's disease. BMB Rep 42:475-481.
21. Brietzke E, Kapczinski F, Grassi-Oliveira R, Grande I, Vieta E, McIntyre RS (2011): Insulin dysfunction and allostatic load in bipolar disorder. Expert Rev Neurother 11:1017-1028.
22. Vincent AM, Russell JW, Low P, Feldman EL (2004): Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 25:612-628.
23. Kim JA, Wei Y, Sowers JR (2008): Role of mitochondrial dysfunction in insulin resistance. Circ Res 102:401-414.
24. Rodriguez-Carrizalez AD, Castellanos-Gonzalez JA, Martinez-Romero EC, Miller-Arrevillaga G, Villa-Hernandez D, Hernandez-Godinez PP, et al. (2013): Oxidants, antioxidants and mitochondrial function in nonproliferative diabetic retinopathy [published online ahead of print July 22]. J Diabetes.
25. Liu Q, Li J, Cheng R, Chen Y, Lee K, Hu Y, et al. (2013): Nitrosative stress plays an important role in Wnt pathway activation in diabetic retinopathy. Antioxid Redox Signal 18:1141-1153.
26. Tiehuis AM, van der GY, Visseren FL, Vincken KL, Biessels GJ, Appelman AP, et al. (2008): Diabetes increases atrophy and vascular lesions on brain MRI in patients with symptomatic arterial disease. Stroke 39:1600-1603.
27. Tiehuis AM, Mali WP, van Raamt AF, Visseren FL, Biessels GJ, van Zandvoort MJ, et al. (2009): Cognitive dysfunction and its clinical and radiological determinants in patients with symptomatic arterial disease and diabetes. J Neurol Sci 283:170-174.
28. Bruehl H, Wolf OT, Sweat V, Tirsi A, Richardson S, Convit A (2009): Modifiers of cognitive function and brain structure in middle-aged and elderly individuals with type 2 diabetes mellitus. Brain Res 1280:186-194.
29. den Heijer T, Vermeer SE, van Dijk EJ, Prins ND, Koudstaal PJ, Hofman A, et al. (2003): Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 46:1604-1610.
30. Gold SM, Dziobek I, Sweat V, Tirsi A, Rogers K, Bruehl H, et al. (2007): Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. Diabetologia 50:711-719.
31. Korf ES, White LR, Scheltens P, Launer LJ (2006): Brain aging in very old men with type 2 diabetes: The Honolulu-Asia Aging Study. Diabetes Care 29:2268-2274.
32. Wrighten SA, Piroli GG, Grillo CA, Reagan LP (2009): A look inside the diabetic brain: Contributors to diabetes-induced brain aging. Biochim Biophys Acta 1792:444-453.
33. Kreis R, Ross BD (1992): Cerebral metabolic disturbances in patients with subacute and chronic diabetes mellitus: Detection with proton MR spectroscopy. Radiology 184:123-130.
34. Lai PH, Chen PC, Chang MH, Pan HB, Yang CF, Wu MT, et al. (2001): In vivo proton MR spectroscopy of chorea-ballismus in diabetes mellitus. Neuroradiology 43:525-531.
35. Kario K, Ishikawa J, Hoshide S, Matsui Y, Morinari M, Eguchi K, et al. (2005): Diabetic brain damage in hypertension: Role of reninangiotensin system. Hypertension 45:887-893.
36. Sarac K, Akinci A, Alkan A, Aslan M, Baysal T, Ozcan C (2005): Brain metabolite changes on proton magnetic resonance spectroscopy in children with poorly controlled type 1 diabetes mellitus. Neuroradiology 47:562-565.
37. Ozsoy E, Doganay S, Dogan M, Alkan A, Firat PG (2012): Evaluation of metabolite changes in visual cortex in diabetic retinopathy by MRspectroscopy. J Diabetes Complications 26:241-245.
38. Sahin I, Alkan A, Keskin L, Cikim A, Karakas HM, Firat AK, Sigirci A (2008): Evaluation of in vivo cerebral metabolism on proton magnetic resonance spectroscopy in patients with impaired glucose tolerance and type 2 diabetes mellitus. J Diabetes Complications 22:254-260.
39. Endicott J, Spitzer RL (1978): A diagnostic interview: The schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 35:837-844.
40. Roy-Byrne P, Post RM, Uhde TW, Porcu T, Davis D (1985): The longitudinal course of recurrent affective illness: Life chart data from research patients at the NIMH. Acta Psychiatr Scand Suppl 317:1-34.
41. Endicott J, Spitzer RL, Fleiss JL, Cohen J (1976): The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 33:766-771.
42. Bifulco A, Bernazzani O, Moran PM, Jacobs C (2005): The childhood experience of care and abuse questionnaire (CECA.Q): Validation in a community series. Br J Clin Psychol 44:563-581.
43. American Diabetes Association (2010): Diagnosis and classification of diabetes mellitus. Diabetes Care 33(suppl 1):S62-S69.
44. Wallace TM, Levy JC, Matthews DR (2004): Use and abuse of HOMA modeling. Diabetes Care 27:1487-1495.
45. Katsuki A, Sumida Y, Gabazza EC, Murashima S, Furuta M, Araki-Sasaki R, et al. (2001): Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care 24:362-365.
46. Sinha DP, Ahmed S, Baneerjee AK, Das M, Hassan H (2009): Significance of an index of insulin resistance in non-diabetic patients with impaired fasting glucose with acute myocardial infarction and its correlation to short term outcome. Indian Heart J 61:40-43.
47. Hajek T, Bernier D, Slaney C, Propper L, Schmidt M, Carrey N, et al. (2008): A comparison of affected and unaffected relatives of patients with bipolar disorder using proton magnetic resonance spectroscopy. J Psychiatry Neurosci 33:531-540.
48. Hajek T, Bauer M, Pfennig A, Cullis J, Ploch J, O'Donovan C, et al. (2012): Large positive effect of lithium on prefrontal cortex Nacetylaspartate in patients with bipolar disorder: 2-centre study. J Psychiatry Neurosci 37:185-192.
49. Phillips ML, Drevets WC, Rauch SL, Lane R (2003): Neurobiology of emotion perception II: Implications for major psychiatric disorders. Biol Psychiatry 54:515-528.
50. McKenna BS, Eyler LT (2012): Overlapping prefrontal systems involved in cognitive and emotional processing in euthymic bipolar disorder and following sleep deprivation: A review of functional neuroimaging studies. Clin Psychol Rev 32:650-663.
51. Mayberg HS (2003): Modulating dysfunctional limbic-cortical circuits in depression: Towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull 65:193-207.
52. Jaeger J, Berns S, Loftus S, Gonzalez C, Czobor P (2007): Neurocognitive test performance predicts functional recovery from acute exacerbation leading to hospitalization in bipolar disorder. Bipolar Disord 9:93-102.
53. Provencher SW (2001): Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 14:260-264.
54. Gruber S, Frey R, Mlynarik V, Stadlbauer A, Heiden A, Kasper S, et al. (2003): Quantification of metabolic differences in the frontal brain of depressive patients and controls obtained by 1H-MRS at 3 Tesla. Invest Radiol 38:403-408.
55. Ongur D, Prescot AP, Jensen JE, Cohen BM, Renshaw PF (2009): Creatine abnormalities in schizophrenia and bipolar disorder. Psychiatry Res 172:44-48.
56. Ongur D (2013): Making progress with magnetic resonance spectroscopy [published online ahead of print October 9]. JAMA Psychiatry.
57. Stork C, Renshaw PF (2005): Mitochondrial dysfunction in bipolar disorder: Evidence from magnetic resonance spectroscopy research. Mol Psychiatry 10:900-919.
58. Frey BN, Stanley JA, Nery FG, Monkul ES, Nicoletti MA, Chen HH, et al. (2007): Abnormal cellular energy and phospholipid metabolism in the left dorsolateral prefrontal cortex of medication-free individuals with bipolar disorder: An in vivo 1H MRS study. Bipolar Disord 9(suppl 1):119-127.
59. Hamakawa H, Kato T, Shioiri T, Inubushi T, Kato N (1999): Quantitative proton magnetic resonance spectroscopy of the bilateral frontal lobes in patients with bipolar disorder. Psychol Med 29:639-644.
60. Deicken RF, Pegues MP, Anzalone S, Feiwell R, Soher B (2003): Lower concentration of hippocampal N-acetylaspartate in familial bipolar I disorder. Am J Psychiatry 160:873-882.
61. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, Wetterslev J (2011): Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 11:CD008143.
62. Yang Y, Song W (2013): Molecular links between Alzheimer's disease and diabetes mellitus. Neuroscience 250C:140-150.
63. Andreazza AC, Kauer-Sant'Anna M, Frey BN, Bond DJ, Kapczinski F, Young LT, Yatham LN (2008): Oxidative stress markers in bipolar disorder: A meta-analysis. J Affect Disord 111:135-144.
64. Kato T, Kato N (2000): Mitochondrial dysfunction in bipolar disorder. Bipolar Disord 2:180-190.
65. Andreazza AC, Shao L, Wang JF, Young LT (2010): Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 67:360-368.
66. Gigante AD, Andreazza AC, Lafer B, Yatham LN, Beasley CL, Young LT (2011): Decreased mRNA expression of uncoupling protein 2, a mitochondrial proton transporter, in post-mortem prefrontal cortex from patients with bipolar disorder and schizophrenia. Neurosci Lett 505:47-51.
67. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM (2007): N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology. Prog Neurobiol 81:89-131.
68. Kemp GJ (2000): Non-invasive methods for studying brain energy metabolism: What they show and what it means. Dev Neurosci 22:418-428.
69. Moller HE, Kurlemann G, Putzler M, Wiedermann D, Hilbich T, Fiedler B (2005): Magnetic resonance spectroscopy in patients with MELAS. J Neurol Sci 229-230:131-139.
70. Ginter E, Simko V (2012): Type 2 diabetes mellitus, pandemic in 21st century. Adv Exp Med Biol 771:42-50.
71. Gazdzinski S, Kornak J, Weiner MW, Meyerhoff DJ (2008): Body mass index and magnetic resonance markers of brain integrity in adults. Ann Neurol 63:652-657.
72. Gazdzinski S, Millin R, Kaiser LG, Durazzo TC, Mueller SG, Weiner MW, Meyerhoff DJ (2010): BMI and neuronal integrity in healthy, cognitively normal elderly: A proton magnetic resonance spectroscopy study. Obesity (Silver Spring) 18:743-748.
73. Bond DJ, Lang DJ, Noronha MM, Kunz M, Torres IJ, Su W, et al. (2011): The association of elevated body mass index with reduced brain volumes in first-episode mania. Biol Psychiatry 70:381-387.
74. Laursen TM, Munk-Olsen T, Gasse C (2011): Chronic somatic comorbidity and excess mortality due to natural causes in persons with schizophrenia or bipolar affective disorder. PLoS One 6:e24597.
75. Druss BG, von Esenwein SA, Compton MT, Rask KJ, Zhao L, Parker RM (2010): A randomized trial of medical care management for community mental health settings: The Primary Care Access, Referral, and Evaluation (PCARE) study. Am J Psychiatry 167:151-159.
76. Nelson SE (2011): Management of patients with type 2 diabetes. Curr Med Res Opin 27:1931-1947.
77. Insel TR, Scolnick EM (2006): Cure therapeutics and strategic prevention: Raising the bar for mental health research. Mol Psychiatry 11:11-17.
78. McIntyre RS, Soczynska JK, Lewis GF, MacQueen GM, Konarski JZ, Kennedy SH (2006): Managing psychiatric disorders with antidiabetic agents: Translational research and treatment opportunities. Expert Opin Pharmacother 7:1305-1321.
79. Ajilore O, Haroon E, Kumaran S, Darwin C, Binesh N, Mintz J, et al. (2007): Measurement of brain metabolites in patients with type 2 diabetes and major depression using proton magnetic resonance spectroscopy. Neuropsychopharmacology 32:1224-1231.
80. Urenjak J, Williams SR, Gadian DG, Noble M (1993): Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 13:981-989.
81. DelBello MP, Cecil KM, Adler CM, Daniels JP, Strakowski SM (2006): Neurochemical effects of olanzapine in first-hospitalization manic adolescents: A proton magnetic resonance spectroscopy study. Neuropsychopharmacology 31:1264-1273.